Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SEP-363856 as adjunctive therapy in major depressive disorder
NCT05593029Phase 2Completed
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization
- Start
- Nov 2022
- Primary completion
- Nov 2025
- Modality
- Small Molecules
- Countries
- 7
01
Overview
A Phase 2 trial of ulotaront in major depressive disorder (MDD), sponsored by Otsuka Pharmaceutical Development & Commercialization. Started Nov 2022; status: completed.
02
Drugs
ulotaront
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT05593029.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05593029.